Research output per year
Research output per year
Personal profile
Headline
ASSOCIATE PROFESSOR
Biography
Fingerprint
Dive into the research topics where Jose Silva is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A noncanonical IRAK4-IRAK1 pathway counters DNA damage–induced apoptosis independently of TLR/IL-1R signaling
Li, Y., Shah, R. B., Sarti, S., Belcher, A. L., Lee, B. J., Gorbatenko, A., Nemati, F., Yu, H., Stanley, Z., Rahman, M., Shao, Z., Silva, J. M., Zha, S. & Sidi, S., 2023, In: Science Signaling. 16, 816Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Zeleke, T. Z., Pan, Q., Chiuzan, C., Onishi, M., Li, Y., Tan, H., Alvarez, M. J., Honan, E., Yang, M., Chia, P. L., Mukhopadhyay, P., Kelly, S., Wu, R., Fenn, K., Trivedi, M. S., Accordino, M., Crew, K. D., Hershman, D. L., Maurer, M. & Jones, S. & 6 others, , Feb 2023, In: Nature Cancer. 4, 2, p. 257-275 19 p.Research output: Contribution to journal › Article › peer-review
Open Access32 Scopus citations -
Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy
Song, W. M., Chia, P. L., Zhou, X., Walsh, M., Silva, J. & Zhang, B., 17 Feb 2023, In: iScience. 26, 2, 106064.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor
Silva, J., Yu, J. & Kalinsky, K., Jun 2023, In: Nature Cancer. 4, 6, p. 809-811 3 p.Research output: Contribution to journal › Letter › peer-review
3 Scopus citations -
The Breast Cancer Single-Cell Atlas: Defining cellular heterogeneity within model cell lines and primary tumors to inform disease subtype, stemness, and treatment options
Dave, A., Charytonowicz, D., Francoeur, N. J., Beaumont, M., Beaumont, K., Schmidt, H., Zeleke, T., Silva, J. & Sebra, R., Jun 2023, In: Cellular oncology (Dordrecht). 46, 3, p. 603-628 26 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations
Press/Media
-
miR-424~503, a group of microRNAs that control the development of a type of breast cancer
6/01/24
1 item of Media coverage
Press/Media
-
New Personalized Medicine Study Findings Have Been Reported by Investigators at Icahn School of Medicine at Mount Sinai (The Breast Cancer Single-cell Atlas: Defining Cellular Heterogeneity Within Model Cell Lines and Primary Tumors To Inform ...)
Sebra, R., Silva, J. & Beaumont , M.
7/02/23
1 item of Media coverage
Press/Media
-
-
Researchers identify a micro-RNA group that controls development of a type of breast cancer
19/10/21
1 item of Media coverage
Press/Media
-
miR-424~503, a group of microRNAs that control the development of a type of breast cancer
15/10/21
1 item of Media coverage
Press/Media